Updates are available Correction dated 2024-08-31
Click to view Correction: https://doi.org/10.1186/s13075-024-03385-8
-
Authors
Brunner, Hermine I
Schulert, Grant S
Sproles, Alyssa
Thornton, Sherry
Cornejo, Gabriel Vega
Antón, Jordi
Cuttica, Ruben
Henrickson, Michael
Foeldvari, Ivan
Kingsbury, Daniel J
Askelson, Margarita
Liu, Jinqi
Mukherjee, Sumanta
Wong, Robert L
Lovell, Daniel J
Martini, Alberto
Ruperto, Nicolino
Grom, Alexei A
,
-
Funding
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (P30 AR076316 and P30 AR070549)
- License Information
-
More Information
Article History
Received: 20 September 2023
Accepted: 26 May 2024
First Online: 25 June 2024
Change Date: 31 August 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13075-024-03385-8
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki [], the International Conference on Harmonisation Guidelines for Good Clinical Practice, and local regulations. At each site, an institutional review board or independent ethics committee approved the protocol, consent forms, and any other written information provided to patients or their legal representatives.
: Not applicable.
: HIB: consultant: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Roche, UCB (funds go to CCHMC/employer); grant/research support: Bristol Myers Squibb, Pfizer (funds go to CCHMC/employer). GSS: speakers bureau: Novartis; consultant: Sobi. GVC: speakers bureau: AbbVie; grant/research support: Bristol Myers Squibb, Eli Lilly, Janssen, Parexel, Sanofi. JA: speakers bureau: AbbVie, Gebro, GlaxoSmithKline, Novartis, Pfizer, Roche, Sobi; consultant: AbbVie, Gebro, GlaxoSmithKline, Novartis, Pfizer, Roche, Sobi; grant/research support: AbbVie, Amgen, Gebro, GlaxoSmithKline, Lilly, Novartis, Novimmune, Pfizer, Roche, Sanofi, Sobi. RC: speakers bureau: AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Lilly, Novartis, Pfizer, Roche, UCB; paid instructor: AbbVie, Novartis, Pfizer, Roche; consultant: AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Lilly, Novartis, Pfizer, Roche, UCB. IF: consultant: Bristol Myers Squibb, Gilead, Hexal, MEDAC, Novartis, Pfizer, Sanofi. DJK: consultant: Pfizer. MA: consultant: Bristol Myers Squibb (working for Syneos Health). JL: employee, shareholder: Bristol Myers Squibb. SM: shareholder: Bristol Myers Squibb; employee, shareholder: GlaxoSmithKline. RLW: employee (at the time of analysis): Bristol Myers Squibb; shareholder: Bristol Myers Squibb. DJL: speakers bureau: Genentech, Wyeth Pharm; consultant: Abbott, AstraZeneca, Boehringer Ingelheim, Celgene, F Hoffmann-La Roche, GlaxoSmithKline, Novartis, Pfizer, Regeneron, UBC, Wyeth Pharma. AM: speakers bureau: AbbVie, Novartis; consultant: AbbVie, Eli Lilly, EMD Serono, Idorsia, Janssen, Novartis, Pfizer. NR: honoraria, speakers bureau, consultant: Ablynx, AstraZeneca-Medimmune, Bayer, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, EMD Serono, F Hoffmann-La Roche, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, R-Pharma, Sinergie, Sobi, UCB; grant/research support: The IRCCS Istituto Giannina Gaslini, where NR works as full-time public employee, has received contributions from: Bristol Myers Squibb, Eli Lilly, F Hoffmann-La Roche, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sobi. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment to third parties. AAG: consultant, grant/research support: AB2Bio, Novartis, Sobi (NovImmune). AS, ST, MH: none declared.
